简介:摘要目的评价中晚期原发性肝癌患者经超选择性肝动脉化疗栓塞介入治疗的方法和疗效。方法收集2004年4月起在本科做介入治疗的36例中晚期肝癌患者的资料。所有患者皆以导管超选择插入肿瘤的供血动脉,以顺铂+氟尿嘧啶+丝裂霉素或表柔比星化疗,再以超液态碘化油、明胶海绵栓塞。结果所有病例皆成功进行了化疗和栓塞治疗。36例患者术后均进行了CT或B超随访,其中瘤体缩小15例>200%,10例>100%,9例>50%,2例缩小不明显。36例患者中,生存期5年以上者9例,3年以上15例,2年以上者8例,12个月以下者4例,其中34例患者术后症状明显减轻,总有效率94.4%,术后无严重并发症。结论超选择肝动脉化疗栓塞术是治疗中晚期原发性肝癌患者的安全、有效的首选方法,可以与外科手术疗效相媲美。
简介:分析不同治疗方案治疗中晚期肝癌的近期及远期临床疗效。选取163例中晚期肝癌患者为研究对象,根据治疗方法不同将患者分为:未治疗组、单纯TACE组、TACE+索拉非尼组、单纯手术组、手术+TACE组、手术+TACE+索拉非尼组。对患者的临床疗效及生存质量进行评价,并应用Kaplan-Meier生存曲线进行生存分析。未治疗组、单纯TACE组、TACE+索拉非尼组、单纯手术组、手术+TACE组、手术+TACE+索拉非尼组的临床有效率(CBR)分别为28.6%、86.7%、90.5%、90.0%、92.9%及93.3%,各治疗组临床有效率均高于未治疗组,差异有统计学意义(P〈0.05),而各治疗组组间的短期临床有效率差异无统计学意义(P〉0.05)。未治疗组、单纯TACE组、TACE+索拉非尼组、单纯手术组、手术+TACE组、手术+TACE+索拉非尼组改善及稳定率分别为42.9%、68.9%、71.4%、70.0%、78.6%及86.7%,手术+TACE+索拉非尼组患者的生存质量优于其他治疗组(P〈0.05)。统计各组患者3年存活率:未治疗组4.3%,单纯TACE组11.1%,TACE+索拉非尼组9.5%,差异无统计学意义(P〉0.05);单纯手术组32.2%、手术+TACE组28.6%、手术+TACE+索拉非尼组46.7%。手术各组患者3年存活率均高于未治疗组,手术+TACE+索拉非尼组患者3年存活率高于单纯手术组及手术+TACE组,差异均有统计学意义(P〈0.05)。中晚期原发性肝癌的治疗效果仍以手术最好,手术联合TACE+索拉非尼在患者的近远疗效均有一定的优势,能显著延长患者的存活率。
简介: 摘要:目的 对中医综合治疗方案治疗原发性中晚期肝癌患者的临床疗效展开评估,为日后的临床治疗提供参考。方法 选择 2018年 3月~ 2020年 3月前来我院治疗的原发性中晚期肝癌患者 100例作为研究对象,随机分为两组,即观察组与对照组。观察组患者给予中医综合治疗方案治疗,对照组给予西医治疗,对比两组患者的临床疗效。结果 经过一段时间的治疗,发现对照组患者的近期疗效优于观察组。在近期治疗中,观察组完全缓解患者 0例,对照组完全缓解 2例;观察组进展患者 17例,对照组为 5例。但是,在治疗结束后,观察组患者的肝功能要优于对照组,观察组达到 A级患者为 35例, B级患者为 18例, C级患者为 7例;对照组 A级患者为 15例, B级患者为 17例, C级患者为 18例。结论 通过应用中医综合治疗方案治疗原发性中晚期肝癌患者,可取得较为理想的治疗效果,帮助患者实现长久的稳步康复,对患者的积极意义较大,今后可在临床治疗中推广应用。 关键词:中医;综合;原发性中晚期肝癌 Abstract: Objective To evaluate the clinical efficacy of comprehensive treatment of traditional Chinese medicine in the treatment of patients with advanced primary liver cancer, so as to provide reference for clinical treatment in the future. Methods from March 2018 to March 2020, 100 patients with advanced primary liver cancer in our hospital were selected and randomly divided into observation group and control group. Patients in the observation group were treated with TCM Comprehensive treatment, while the control group were treated with western medicine. The clinical efficacy of the two groups was compared. Results after a period of treatment, it was found that the short-term efficacy of the control group was better than that of the observation group. In the short-term treatment, there were 0 cases of complete remission in the observation group and 2 cases in the control group; there were 17 cases in the observation group and 5 cases in the control group. However, at the end of treatment, the liver function of the observation group was better than that of the control group, with 35 cases of Grade A patients, 18 cases of B-level patients and 7 cases of C-level patients in the observation group; 15 cases of A-level patients, 17 cases of B-level patients and 18 cases of C-level patients in the control group. Conclusion through the application of TCM Comprehensive treatment program in the treatment of patients with primary liver cancer in the middle and advanced stage, it can achieve ideal treatment effect, help patients to achieve long-term and stable recovery, which has great positive significance for patients, and can be applied in clinical treatment in the future.
简介:目的:探讨联合化疗治疗中晚期原发性肝癌的效果。方法:于2014年03月--2018年03月收治的45例中晚期原发性肝癌患者为研究对象。化疗方案FOLFOX4治疗23例和XELOX化疗方案治疗22例。以Child-Pugh标准,将肝癌患者分为两组,即A组(Child-PughA级,20例)、B组(Child-PughB级,25例)。结果:两组疾病控制率无差异(p>0.05);A组肝毒性、消化道反应等发生率低于B组,有差异统计学意义(p<0.05)。结论:对于中晚期原发性肝癌患者,联合化疗有利于控制疾病进展,效果显著。但相比于Child-PughB级而言,Child-PughA级中晚期原发性肝癌患者获益更大。
简介:摘要目的研究中西医治疗对中晚期原发性肝癌患者生活质量和生存期的影响。方法中晚期原发性肝癌患者105例,随机分为3组A组(中西结合组共48例)予自拟肝积方结合TACE联合氩氦刀治疗;B组(中医组共32例)以肝积方治疗;C组(西医组25例)予TACE联合氩氦刀治疗。观察患者近期疗效,KPS评分和生活质量(QOL)评分变化,追踪生存期。结果近期疗效三组比较无明显差异(P>0.05);治疗前后KPS评分A、B组治疗后有提高(A>B),C组下降,三组差值比较有显著差别(P<0.05)。治疗前后生活质量(QOL)评分A、B组治疗后有提高(A>B),C组下降,三组差值比较有显著差别。(P<0.05)。远期疗效平均生存时间、中位生存期、0.5年生存率、1年生存率均呈A>B>C组(P<0.01)。结论本研究显示中晚期原发性肝癌接受中西结合、中医、西医治疗其近期肿瘤控制率相当,但患者生活质量、生存期中西结合组优于中医组,中医组又优于西医组。
简介:摘要目的分析肝动脉化疗栓塞联合放疗对中晚期原发性肝癌的疗效。方法选取2016年4月至2018年3月我院收治的32例中晚期原发性肝癌患者作为研究对象,回顾性分析其病历资料,按照治疗方式的不同将其分成两组,一组采用肝动脉化疗栓塞联合放疗治疗,为研究组,一组采用肝动脉化疗栓塞进行治疗,为对照组,比较两组患者的治疗效果。结果研究组患者的治疗有效率为77.78%(14/18),明显高于对照组的35.71%(5/14)(P<0.05);研究组的三年生存率为66.67%(12/18),与对照组比较存在统计学意义(P<0.05)。结论肝动脉化疗栓塞联合放疗对中晚期原发性肝癌临床效果良好,能够显著提高患者的生存周期,其效果优于单独的化疗治疗。
简介: 【摘 要】目的:分析原发性肝癌中晚期患者应用介入治疗对肝功能的影响。方法:我院 2017年 7月至 2019年 7月接收原发性肝癌中晚期患者 82例。采用随机分组原理分为对照组与观察组,两组均 41例。对照组采取常规方法治疗,观察组则应用介入方法治疗。对比分析临床效率与肝功能情况。结果:观察组与对照组治疗有效率分别为 92.7%与 82.9%,统计分析 P<0.05,符合统计学意义 ;相比较治疗前,治疗后两组患者 ALT、 ALB与 TBIL均改善,且观察组患者改善要显著优于对照组,符合统计学意义( P<0.05)。结论:与临床常规方法相比较,介入治疗原发性肝癌中晚期患者可提高临床效率,改善患者肝功能,应用价值较高。 【关键词】介入治疗 ;原发性肝癌 ;肝功能 [Abstract] Objective: to analyze the effect of interventional therapy on liver function in patients with advanced primary liver cancer. Methods: from July 2017 to July 2019, our hospital received 82 patients with advanced primary liver cancer. According to the principle of random grouping, 41 cases were divided into control group and observation group. The control group was treated with conventional methods, while the observation group was treated with interventional methods. Comparative analysis of clinical efficiency and liver function. Results: the effective rate of treatment in the observation group and the control group was 92.7% and 82.9% respectively, statistical analysis P < 0.05, consistent with statistical significance; before treatment, the alt, ALB and TBIL in the two groups were improved, and the improvement in the observation group was significantly better than that in the control group, consistent with statistical significance (P < 0.05). Conclusion: compared with the routine clinical methods, interventional therapy can improve the clinical efficiency and liver function of patients with primary liver cancer.